en · de · es · fr · pt
compound-index.peptides1126.com › Data › Background And Chemical Profile — Complete Guide

Background And Chemical Profile — Complete Guide

By Editorial Desk · published 2025-09-26 · last reviewed 2025-10-26 · Data

melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-10-26. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Chemical Profile

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Regulation, Literature and Verification

Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.

Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.

Melanotan-2 at a glance

PropertyValueNotes
Molecular classSynthetic cyclic heptapeptideAnalog of alpha-MSH with an internal lactam bridge
Molecular weightApproximately 1024 daltonsFree base value; salt forms differ
AppearanceWhite to off-white powderUsually supplied as a lyophilized solid
SolubilityFreely soluble in waterPoorly soluble in nonpolar solvents
Typical storage−20 °C, dry, protected from lightRepeated freeze-thaw cycles degrade peptides

Melanotan-2 Structure and Receptor Pharmacology

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Related pages on this site

Handling, Storage and Analytical Control

Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.

Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Quality Control and Analytical Practice

Regulatory status differs by country, and in many places supplying the compound for human consumption is unlawful. Vendors frequently label material as intended for research use only, a designation that shifts stated purpose but does not create a legal pathway for personal use. Certificates of analysis accompanying such products vary widely in detail and provenance. Third-party testing exists but is voluntary, and results are rarely linked to a specific lot in a publicly verifiable way.

Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Background from the literature

Gyrification The process by which the cerebral cortex develops folds (gyri) and grooves (sulci) during brain development. Gyrification increases the surface area of the brain, allowing for greater cognitive capacity within the limited volume of the skull.

In a letter to Chancellor Rachel Reeves, a group of the UK's high street retailers has warned the "cumulative burden" of tax rises announced in the October budget, as well as other policies already in the pipeline, will add billions in costs to the retail sector and put jobs at risk. The UK government estimates that 50,000 pensioners will be living in poverty in 2025 as a result of cuts to winter fuel payments. 20 November Inflation rises from 1.7% to 2.3%, its highest level in six months, driven by rising energy costs. Harrods' newly appointed survivors' advocate Dame Jasvinder Sanghera tells BBC Radio 4's The World at One that Mohamed Al Fayed's sexual abuse could be "something on the scale of Jimmy Savile". UK-supplied Storm Shadow missiles, with a significantly longer range than earlier weapons, are reportedly used for the first time by Ukraine to strike inside Russia. Defence Secretary John Healey announces the early decommissioning of some older defence equipment, such as ships, drones and helicopters in order to save £500m, and despite an "increasing global threat" facing the UK. 21 November A Briton, 28-year-old Simone White, is among those reported to have died in a mass poisoning in Laos. A report by the Charity Commission into activities at the Captain Sir Tom Moore Foundation finds that Hannah and Colin Ingram-Moore (Moore's daughter and son-in-law) benefited from their association with the charity, including money from a £1.4m book deal paid to a family company, not to the Foundation.

=== Reproduction === Due to its geographic ranges, arapaima's lifecycle is greatly affected by seasonal flooding. Various pictures show slightly different coloring owing to colour changes when they reproduce. The arapaima lays its eggs when water levels are low or beginning to rise. They build a nest about 50 cm (20 in) wide and 15 cm (5.9 in) deep, usually in muddy-bottomed areas. As the water rises, the eggs hatch and the offspring have the flood season from May to August in which to prosper, such that yearly spawning is regulated seasonally.

In 1956, Crick and Watson speculated on the structure of small viruses. They suggested that spherical viruses such as Tomato bushy stunt virus had icosahedral symmetry and were made from 60 identical subunits. After his short time in New York, Crick returned to Cambridge where he worked until 1976, at which time he moved to California. Crick engaged in several X-ray diffraction collaborations such as one with Alexander Rich on the structure of collagen. However, Crick was quickly drifting away from continued work related to his expertise in the interpretation of X-ray diffraction patterns of proteins. George Gamow established a group of scientists interested in the role of RNA as an intermediary between DNA as the genetic storage molecule in the nucleus of cells and the synthesis of proteins in the cytoplasm (the RNA Tie Club). It was clear to Crick that there had to be a code by which a short sequence of nucleotides would specify a particular amino acid in a newly synthesised protein. In 1956, Crick wrote an informal paper about the genetic coding problem for the small group of scientists in Gamow's RNA group. In this article, Crick reviewed the evidence supporting the idea that there was a common set of about 20 amino acids used to synthesise proteins. Crick proposed that there was a corresponding set of small "adaptor molecules" that would hydrogen bond to short sequences of a nucleic acid, and also link to one of the amino acids. He also explored the many theoretical possibilities by which short nucleic acid sequences might code for the 20 amino acids.

Sources: en.wikipedia.org

Further detail

=== Lysostaphin === The lysostaphin test is used to differentiate between Staphylococcus and Micrococcus bacteria. Lysostaphin can lyse Staphylococcus, but Micrococcus bacteria are resistant to the chemical.

HCl + NaHCO3 → NaCl + H2CO3 The carbonic acid rapidly equilibrates with carbon dioxide and water through catalysis by carbonic anhydrase enzymes bound to the gut epithelial lining, leading to a net release of carbon dioxide gas within the lumen associated with neutralisation. In the absorptive upper intestine, such as the duodenum, both the dissolved carbon dioxide and carbonic acid will tend to equilibrate with the blood, leading to most of the gas produced on neutralisation being exhaled through the lungs.

Siege life took its toll on the defending soldiers and civilians, as food began to grow scarce after a few weeks. In Mafeking, Sol Plaatje wrote, "I saw horseflesh for the first time being treated as a human foodstuff." The cities also dealt with constant artillery bombardment, making the streets dangerous. Near the end of the siege of Kimberley, it was expected that the Boers would intensify their bombardment, so Rhodes displayed a notice encouraging people to go down into shafts of the Kimberley Mine for protection. The townspeople panicked, and people surged into the mineshafts constantly for a 12-hour period. Although the bombardment never came, this did nothing to diminish the anxious civilians' distress. The most well-heeled of the townspeople, including Rhodes, sheltered in the Sanatorium, site of the present-day McGregor Museum; the poorer residents, notably the black population, did not have any shelter from shelling. In retrospect, the Boers' decision to commit themselves to sieges (Sitzkrieg) was a mistake and an illustration of their lack of strategic vision. Of the seven sieges in the First Boer War, the Boers had prevailed in none. More importantly, it handed the initiative back to the British and allowed them to recover. Generally throughout the campaign, the Boers were too defensive and passive, wasting the opportunities they had for victory. Yet that passivity testified to the fact they had no desire to conquer British territory, but only to preserve their ability to rule in their own territory.

== Disorder and disease == Intrinsically unstructured proteins have been implicated in a number of diseases. Aggregation of misfolded proteins is the cause of many synucleinopathies and toxicity as those proteins start binding to each other randomly and can lead to cancer or cardiovascular diseases. Thereby, misfolding can happen spontaneously because millions of copies of proteins are made during the lifetime of an organism. The aggregation of the intrinsically unstructured protein α-synuclein is thought to be responsible. The structural flexibility of this protein together with its susceptibility to modification in the cell leads to misfolding and aggregation. Genetics, oxidative and nitrative stress as well as mitochondrial impairment impact the structural flexibility of the unstructured α-synuclein protein and associated disease mechanisms. Many key tumour suppressors have large intrinsically unstructured regions, for example p53 and BRCA1. These regions of the proteins are responsible for mediating many of their interactions. Taking the cell's native defense mechanisms as a model drugs can be developed, trying to block the place of noxious substrates and inhibiting them, and thus counteracting the disease.

== Age and breed prevalence == PPID has been diagnosed in horses as young as 7 years old, although most horses are first diagnosed at ages 19 to 20. An estimated 21% of horses older than 15 years have PPID. All breeds may develop PPID, but pony breeds and Morgans seem to be more commonly affected.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2?

It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.

How does it differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.

Is it the same as bremelanotide?

No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.

Has it been tested in clinical trials?

Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.

Network